Australia Markets closed

Seres Therapeutics, Inc. (MCRB)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
10.68-0.75 (-6.56%)
At close: 04:00PM EST
10.99 +0.31 (+2.90%)
After hours: 07:52PM EST
Full screen
Trade prices are not sourced from all markets
Previous close11.43
Open11.40
Bid10.60 x 1000
Ask11.50 x 1200
Day's range10.55 - 11.69
52-week range5.41 - 29.90
Volume2,526,710
Avg. volume1,939,290
Market cap978.178M
Beta (5Y monthly)3.99
PE ratio (TTM)N/A
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • Motley Fool

    Why Shares of Seres Therapeutics Rose More Than 21% on Tuesday

    Shares of Seres Therapeutics (NASDAQ: MCRB) climbed more than 21% on Tuesday. The biotech stock, which closed at $8.82 on Monday, opened at $8.63 on Tuesday, then took off, climbing to a daily high of $10.78 in the afternoon. The move was in direct contrast to the general market trend with both the Dow Jones Industrial Average and S&P 500 index down for the day.

  • Motley Fool

    Why Shares of Seres Therapeutics Are Up More Than 22% Wednesday

    The company's revenue was $126.7 million, compared with only $1.4 million year over year, with most of the increase from collaboration revenue from Seres' co-commercialization license agreement with NestlΓ© Health Science. The improved financial numbers were only part of the story. On Wednesday, Seres said it had established a collaboration with Swiss pharmaceutical company Bacthera to manufacture SER-109, Seres' lead therapy to treat recurrent Clostridioides difficle infection (rCDI).

  • Zacks

    Seres Therapeutics (MCRB) Q3 Earnings and Revenues Beat Estimates

    Seres Therapeutics (MCRB) delivered earnings and revenue surprises of 253.19% and 1681.10%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?